Sensorion to Host SENS-601 Program Day on GJB2-Related Hearing Loss Gene Therapy
Sensorion (FR001401A9Z0 – ALSEN), a clinical-stage biotechnology company focused on developing novel therapies designed to restore, treat, and prevent hearing loss disorders, has announced registration and connection details for its upcoming SENS-601 Program Day, scheduled for September 22, 2026.
The virtual event will focus exclusively on Sensorion’s SENS-601 program, an investigational gene therapy approach being developed for GJB2-related hearing loss. The program day is intended to provide investors, analysts, researchers, healthcare professionals, and other interested stakeholders with a detailed overview of the scientific rationale behind SENS-601, the patient population that may benefit from the therapy, and the design and endpoints of the company’s HearConnex clinical trial.
Sensorion said the event will bring together members of its management team and two external scientific and clinical experts. The speakers include Professor Christine Petit of the Institut Pasteur – Institut de l’Audition / Institut reConnect and Dr. Sharon Cushing of The Hospital for Sick Children in Toronto, who serves as the Coordinating Investigator for the HearConnex trial.
The event is expected to provide additional context around the development of SENS-601 and the broader scientific landscape surrounding genetic forms of hearing loss.
Focus on GJB2-Related Hearing Loss
GJB2-related hearing loss is associated with variants in the GJB2 gene, which encodes connexin 26, a protein that plays an important role in communication between cells within the inner ear. Genetic alterations affecting GJB2 can result in hearing impairment, including forms of congenital or early-onset sensorineural hearing loss.
Sensorion is developing SENS-601 as a gene therapy designed to address the underlying genetic cause of GJB2-related hearing loss. The company’s approach reflects a broader movement in biotechnology toward developing therapies that target the molecular mechanisms responsible for inherited disorders rather than focusing solely on managing their symptoms.
For people affected by genetic hearing loss, treatment options can vary depending on the underlying cause, severity, age of onset, and individual clinical circumstances. The development of targeted gene therapies has generated interest because such approaches may potentially address specific genetic defects that contribute to hearing impairment.
Sensorion’s SENS-601 program is therefore an important component of the company’s broader research strategy in hearing disorders. The upcoming program day will provide an opportunity for the company and its external experts to explain the scientific basis of the therapy and the clinical development strategy being pursued.
HearConnex Trial to Be Discussed
A central topic of the SENS-601 Program Day will be the HearConnex trial, including its design and clinical endpoints.
Clinical trial design is an important consideration in the development of gene therapies for hearing loss. Researchers must evaluate not only safety and tolerability but also whether an investigational treatment can produce meaningful improvements in hearing-related outcomes.
During the event, Sensorion’s management and invited experts are expected to discuss the patient population being studied and the rationale behind the selected clinical endpoints. Details concerning trial methodology can help stakeholders better understand how the company intends to evaluate the potential clinical benefits of SENS-601.
Dr. Sharon Cushing, Coordinating Investigator for HearConnex and a specialist at The Hospital for Sick Children in Toronto, will participate in the event alongside Sensorion’s management team. Her involvement is expected to provide an external clinical perspective on the trial and the patient population targeted by the program.
Professor Christine Petit will also participate. Her affiliation with the Institut Pasteur, Institut de l’Audition, and Institut reConnect brings additional expertise in hearing science and the biological mechanisms associated with auditory disorders.
External Experts to Join Sensorion Management
The participation of recognized external experts is intended to broaden the discussion beyond the company’s internal development activities.
Professor Christine Petit is associated with research into the biological and genetic mechanisms underlying hearing and hearing disorders. Her participation will provide scientific context for the development of therapies targeting genetic causes of hearing impairment.
Dr. Sharon Cushing, meanwhile, brings clinical expertise and direct involvement in the HearConnex program as its Coordinating Investigator. Her participation is expected to provide insight into the clinical development of SENS-601 and the practical considerations involved in evaluating an investigational therapy in patients with GJB2-related hearing loss.
Together with Sensorion’s management, the speakers will address the scientific foundation of SENS-601, the characteristics of the targeted patient population, and the design and endpoints of the HearConnex study.
Registration Required for Webcast and Q&A
The SENS-601 Program Day will take place on September 22, 2026, at 2:30 p.m. Central European Time (CET), corresponding to 8:30 a.m. Eastern Time (ET).
Advance registration is required to participate in the webcast. Following registration, participants will be able to access the online presentation during the scheduled event.
The program will also include a question-and-answer session, for which conference-call registration is required. This portion of the event will provide an opportunity for participants to hear responses to questions concerning the SENS-601 program, the HearConnex trial, and the development strategy for the investigational therapy.
Sensorion has also confirmed that a replay of the webcast will be made available on the company’s website following the event. This will allow individuals who are unable to attend the live presentation to access the information afterward.
Full details regarding the program, including the event agenda and participation information, are available through Sensorion’s corporate website.
Gene Therapy as a Potential Approach to Hearing Disorders
The development of SENS-601 forms part of a wider effort within the biotechnology sector to apply gene therapy technologies to inherited diseases. In hearing disorders, genetic research has helped identify specific mutations and biological pathways associated with hearing impairment, creating opportunities to investigate targeted therapeutic approaches.
GJB2-related hearing loss represents one such area where understanding the genetic basis of disease can inform the development of potential treatments. By focusing on a defined genetic cause, Sensorion is pursuing a precision approach intended for a specific patient population.
However, as with other investigational gene therapies, the clinical development process will be important in determining the safety, tolerability, feasibility, and potential efficacy of SENS-601. The HearConnex trial is expected to provide clinical data that will contribute to understanding how the therapy performs in patients with GJB2-related hearing loss.
The upcoming program day will therefore be closely focused on the scientific and clinical development of SENS-601 rather than on broader company activities.
Sensorion’s Hearing Loss Development Strategy
Sensorion specializes in the development of therapeutic approaches for hearing loss and related disorders. Its research strategy includes efforts aimed at restoring, treating, and preventing hearing impairment through innovative therapeutic technologies.
The SENS-601 program represents the company’s focus on genetically driven hearing loss and reflects the potential of precision medicine approaches within the field of auditory disorders.
By bringing together company representatives and independent experts, Sensorion intends to provide stakeholders with a more detailed understanding of the program and its clinical development pathway. The discussion of the underlying science, patient population, and HearConnex trial design is expected to offer additional information about the rationale for SENS-601 and the objectives of its ongoing development.
The SENS-601 Program Day will be held on September 22, 2026, at 2:30 p.m. CET / 8:30 a.m. ET, with advance registration required for the webcast and separate registration required for the Q&A conference call. A replay will subsequently be made available on Sensorion’s website.
The event represents an opportunity for the biotechnology and hearing-loss research communities to learn more about Sensorion’s investigational gene therapy program and its clinical strategy for addressing GJB2-related hearing loss.
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore hearing, and treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of 3 inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. SENS-601 (GJB2-GT) is the Company’s lead gene therapy program, targeting hearing loss related to mutations in the GJB2 gene to address important hearing loss segments in adults and children developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur.
Sensorion’s pipeline also consists of a clinical-stage small molecule program, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion’s small molecule progressed in three Phase II proof of concept clinical studies: firstly, in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing, with analysis completed in Q1 2026. Secondly, with partner Cochlear Limited, a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation, completed in 2024. Thirdly, a Phase II study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in 2022.